2000 Simpsonwood CDC conference

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

Retrieved on: 
Monday, March 28, 2022

SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety. All efficacy endpoints were exploratory as the study was not powered to detect treatment differences. In the study of 63 randomized patients, 31% were admitted to the ICU prior to initiation of treatment. The WHO ordinal scale indicated severe disease in 82% of patients (range: 0-8, median 5).

Key Points: 
  • In the study of 63 randomized patients, 31% were admitted to the ICU prior to initiation of treatment.
  • The WHO ordinal scale indicated severe disease in 82% of patients (range: 0-8, median 5).
  • Safety: The results from the INSPIRE trial suggest that CAP-1002 was safe, well tolerated and consistent with the historically observed safety profile of this therapy.
  • Exploratory Efficacy: Overall mortality in the study was 20%, with 6 deaths in the placebo group and 5 deaths in the CAP-1002 group.

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

Retrieved on: 
Friday, September 24, 2021

The significance of this data is vitally important to patients and the DMD community.

Key Points: 
  • The significance of this data is vitally important to patients and the DMD community.
  • The data suggests that CAP-1002 slowed the decline of DMD in patients for whom few options currently exist, said Dr. Linda Marbn, Ph.D., Chief Executive Officer of Capricor.
  • This is the second clinical trial investigating CAP-1002 showing similar results in the treatment of DMD patients.
  • Capricor completed the HOPE-Duchenne (Phase 1/2) trial in 2019, the results of which were published in Neurology , the medical journal of the American Academy of Neurology.